Your browser doesn't support javascript.
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee, Rebecca J; Wysocki, Oskar; Zhou, Cong; Shotton, Rohan; Tivey, Ann; Lever, Louise; Woodcock, Joshua; Albiges, Laurence; Angelakas, Angelos; Arnold, Dirk; Aung, Theingi; Banfill, Kathryn; Baxter, Mark; Barlesi, Fabrice; Bayle, Arnaud; Besse, Benjamin; Bhogal, Talvinder; Boyce, Hayley; Britton, Fiona; Calles, Antonio; Castelo-Branco, Luis; Copson, Ellen; Croitoru, Adina E; Dani, Sourbha S; Dickens, Elena; Eastlake, Leonie; Fitzpatrick, Paul; Foulon, Stephanie; Frederiksen, Henrik; Frost, Hannah; Ganatra, Sarju; Gennatas, Spyridon; Glenthøj, Andreas; Gomes, Fabio; Graham, Donna M; Hague, Christina; Harrington, Kevin; Harrison, Michelle; Horsley, Laura; Hoskins, Richard; Huddar, Prerana; Hudson, Zoe; Jakobsen, Lasse H; Joharatnam-Hogan, Nalinie; Khan, Sam; Khan, Umair T; Khan, Khurum; Massard, Christophe; Maynard, Alec; McKenzie, Hayley.
  • Lee RJ; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Wysocki O; The University of Manchester, Manchester, United Kingdom.
  • Zhou C; The University of Manchester, Manchester, United Kingdom.
  • Shotton R; Cancer Research UK Manchester Institute Cancer Biomarker Center, The University of Manchester, Alderley Park, United Kingdom.
  • Tivey A; Cancer Research UK Manchester Institute Cancer Biomarker Center, The University of Manchester, Alderley Park, United Kingdom.
  • Lever L; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Woodcock J; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Albiges L; The University of Manchester, Manchester, United Kingdom.
  • Angelakas A; The University of Manchester, Manchester, United Kingdom.
  • Arnold D; The University of Manchester, Manchester, United Kingdom.
  • Aung T; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Banfill K; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Baxter M; Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Hamburg, Germany.
  • Barlesi F; Weston Park Cancer Center, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Bayle A; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Besse B; The University of Manchester, Manchester, United Kingdom.
  • Bhogal T; Division of Molecular and Clinical Medicine, Ninewells School of Medicine, University of Dundee, Dundee, United Kingdom.
  • Boyce H; Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Britton F; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
  • Calles A; Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France.
  • Castelo-Branco L; Oncostat U1018, Inserm, Paris-Saclay University, Labeled Ligue Contre le Cancer, Villejuif, France.
  • Copson E; Drug Development Department (DITEP) Gustave Roussy-Cancer Campus, Villejuif, France.
  • Croitoru AE; The Clatterbridge Cancer Center NHS Foundation Trust, Liverpool, United Kingdom.
  • Dani SS; Weston Park Cancer Center, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Dickens E; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Eastlake L; Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Fitzpatrick P; ESMO-CoCARE Steering Committee, European Society for Medical Oncology, Lugano, Switzerland.
  • Foulon S; NOVA National School of Public Health, Lisboa, Portugal.
  • Frederiksen H; Department of Medical Oncology, University Hospital Center of Algarve, Faro, Portugal.
  • Frost H; Cancer Sciences Academic Unit, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Ganatra S; Medical Oncology Department, Fundeni Clinical Institute, Bucuresti, Romania.
  • Gennatas S; Lahey Hospital and Medical Center, Burlington, MA.
  • Glenthøj A; Oncology Department, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
  • Gomes F; University Hospitals Plymouth NHS Trust, Crownhill, Plymouth, Devon, United Kingdom.
  • Graham DM; Cancer Research UK Manchester Institute Cancer Biomarker Center, The University of Manchester, Alderley Park, United Kingdom.
  • Hague C; Oncostat U1018, Inserm, Paris-Saclay University, Labeled Ligue Contre le Cancer, Villejuif, France.
  • Harrington K; Biostatistics and Epidemiology Office, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Harrison M; Department of Haematology, Odense University Hospital, Odense, Denmark.
  • Horsley L; Cancer Research UK Manchester Institute Cancer Biomarker Center, The University of Manchester, Alderley Park, United Kingdom.
  • Hoskins R; Lahey Hospital and Medical Center, Burlington, MA.
  • Huddar P; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Hudson Z; Department of Haematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Jakobsen LH; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Joharatnam-Hogan N; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Khan S; The University of Manchester, Manchester, United Kingdom.
  • Khan UT; The Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Khan K; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Massard C; The Institute of Cancer Research NIHR Biomedical Research Center, London, United Kingdom.
  • Maynard A; Ninewells Hospital and Medical School, Dundee, United Kingdom.
  • McKenzie H; The Christie NHS Foundation Trust, Manchester, United Kingdom.
JCO Clin Cancer Inform ; 6: e2100177, 2022 05.
Article in English | MEDLINE | ID: covidwho-2196620
ABSTRACT

PURPOSE:

Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET).

METHODS:

Patients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (≥ 24 hours inpatient), oxygen (O2) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort.

RESULTS:

The model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation.

CONCLUSION:

CORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JCO Clin Cancer Inform Year: 2022 Document Type: Article Affiliation country: CCI.21.00177

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Language: English Journal: JCO Clin Cancer Inform Year: 2022 Document Type: Article Affiliation country: CCI.21.00177